For instance, the CD8+ T cell localisation at tumour margins and within the tumour prior to ICT correlated positively with a robust response to immunotherapy [9], whilst regulatory T lymphocytes (Tregs) blunting the effector immune functions contributed to the clinical failure of ICT [10]. The gene discussed is CD8A; the disease is neoplasm.